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Background
The therapeutic use of small interfering RNAs (siRNA) to
prevent or treat HIV infection requires an effective means
for in vivo delivery into susceptible target cells. Transfec-
tion of lymphocytes is especially difficult, even in vitro.
Aptamers, which are small structured nucleic acid
sequences that bind with high specificity to individual
proteins, provide an attractive approach for cell-specific
targeting.
Methods
We designed a chimeric RNA, which was transcribed in
vitro. It was composed of a CD4-specific aptamer fused to
the 21 nucleotide passenger siRNA strand, and then com-
plexed with the complementary 21 nucleotide active
siRNA strand. We hypothesized that the partially-
duplexed RNA would be selectively internalized into
CD4+ cells following receptor binding to the aptamer,
and would be subsequently processed by Dicer into an
active siRNA capable of knocking down target genes.
Results
Specific delivery and knockdown was first evaluated by
comparing lamin expression, measured by RT-PCR and
Western blot, in HeLa cells stably transfected to express
CD4 or control CD4- HeLa cells treated with CD4
aptamer-lamin siRNA chimeras. Lamin gene silencing was
observed in CD4+ HeLa cells, but not in CD4- HeLa cells,
and required both the CD4-aptamer and the lamin siRNA.
Similarly, lamin expression was knocked down in primary
CD4+ T-cells and macrophages. To investigate whether
this system could be used to suppress HIV infection, CD4-
aptamer chimeras were designed to encode siRNAs target-
ing the viral genes gag, vif and the HIV co-receptor, CCR5.
Anti-HIV RNAs, alone and in combination, inhibited HIV
infection, as monitored by intracellular p24 staining and
p24 ELISA, in primary macrophages and CD4+ T-cells by
70–90%. Preliminary data also suggest efficient inhibi-
tion of HIV transmission to polarized human cervical
explants.
Conclusion
These findings suggest that siRNA-aptamer chimeric RNAs
could be an effective, cell-type specific therapeutic gene
silencing approach to prevent HIV transmission or treat
HIV infection.
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